HC Wainwright Forecasts LifeMD’s Q2 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for LifeMD in a research report issued to clients and investors on Wednesday, May 7th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.02 per share for the quarter, down from their prior forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.17 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.16 EPS and Q4 2026 earnings at $0.22 EPS.

LifeMD (NASDAQ:LFMD) last released its earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to analysts’ expectations of $62.47 million.

Several other equities research analysts have also commented on the company. B. Riley raised LifeMD to a “strong-buy” rating in a research note on Tuesday, March 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price objective on shares of LifeMD in a research report on Tuesday, March 11th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LifeMD has an average rating of “Buy” and a consensus price target of $11.00.

LifeMD Stock Up 1.2%

Shares of LFMD stock opened at $8.26 on Monday. The stock has a market capitalization of $375.40 million, a PE ratio of -12.91 and a beta of 2.22. LifeMD has a 52-week low of $3.99 and a 52-week high of $9.87. The stock’s 50-day moving average price is $5.86 and its 200 day moving average price is $5.70.

Insider Activity at LifeMD

In other news, CEO Justin Schreiber sold 21,995 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $7.53, for a total transaction of $165,622.35. Following the sale, the chief executive officer now directly owns 2,553,726 shares of the company’s stock, valued at $19,229,556.78. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Jessica Friedeman sold 30,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the transaction, the chief marketing officer now owns 170,000 shares in the company, valued at $962,200. This represents a 15.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 151,995 shares of company stock valued at $1,101,922 over the last quarter. 15.97% of the stock is owned by company insiders.

Institutional Investors Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently made changes to their positions in LFMD. Royce & Associates LP increased its stake in LifeMD by 3.5% in the 1st quarter. Royce & Associates LP now owns 1,155,231 shares of the company’s stock valued at $6,284,000 after buying an additional 39,240 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of LifeMD by 21.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 931,294 shares of the company’s stock worth $4,610,000 after buying an additional 165,378 shares during the period. Millennium Management LLC boosted its holdings in shares of LifeMD by 17.1% during the 4th quarter. Millennium Management LLC now owns 885,987 shares of the company’s stock worth $4,386,000 after buying an additional 129,327 shares during the period. Geode Capital Management LLC boosted its holdings in LifeMD by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock valued at $4,071,000 after purchasing an additional 2,984 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in LifeMD by 45.2% in the 4th quarter. Renaissance Technologies LLC now owns 510,000 shares of the company’s stock valued at $2,524,000 after purchasing an additional 158,796 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.